CGC

Business Context and Reporting Period

Company: Canopy Growth Corp (CGC)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended June 30, 2025 (Fiscal Q1 2026)
Reporting Currency: Canadian Dollars (CAD), unless otherwise noted.
Business Overview: Canopy Growth is a global cannabis company producing, distributing, and selling cannabis products for adult-use and medical purposes, alongside vaporizers and accessories via its Storz & Bickel segment. The company operates primarily in Canada, Europe, and Australia, and holds a non-controlling interest in Canopy USA, LLC, which manages U.S. cannabis investments (including Acreage, Wana, and Jetty).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 9% year-over-year (YoY) to $72.1 million. The Cannabis segment drove growth with a 24% increase ($57.0M), led by Canadian adult-use (+43%) and medical (+13%) sales. Conversely, the Storz & Bickel segment declined 25% to $15.2M due to economic uncertainty and lapping strong prior-year sales.
• Margin Compression: Gross margin percentage decreased 1,000 basis points to 25%. This was attributed to costs associated with new product launches, shifts in product/geographic mix, and increased freight costs.
• Reduced Net Loss: Net loss from continuing operations improved significantly by 68% to $41.5 million. This improvement was primarily driven by a $75.3 million reduction in "Other income (expense), net," largely due to decreased non-cash fair value losses on Canopy USA-related assets compared to the prior year.
• Operating Expenses: Total operating expenses decreased 22% to $40.7 million. Selling, general, and administrative (SG&A) expenses dropped 21% due to headcount reductions and lower third-party costs. Share-based compensation reversed to a benefit of $(0.1) million due to executive departures and higher estimated forfeitures.
• Restructuring Costs: The company recorded a $2.7 million loss on asset impairment and restructuring, primarily for employee restructuring costs, compared to $0.02 million in the prior year.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Status: Management previously raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and debt obligations. However, this doubt has been alleviated following the sale of shares under the February 2025 ATM Program (raising ~$38.3M) and ongoing cost-saving measures.
• Liquidity Strategy: The company continues to pursue cost savings and additional financing. As of August 6, 2025, the company has sold ~$130.9M under the February 2025 ATM Program, with ~$105.6M remaining available.
• Debt Management: The company entered into a "Third Paydown Agreement" in July 2025, requiring prepayments of US$50 million on its Credit Facility by March 31, 2026. The first tranche of US$25 million was paid in July 2025. Additionally, Acreage (a Canopy USA subsidiary) secured additional financing, resolving a previous default status.
• Legal Proceedings: The company is subject to ongoing SEC investigations regarding the BioSteel revenue recognition review and several putative class action lawsuits alleging misrepresentations regarding financial disclosures and product costs (e.g., Claybourne launch). The company denies misconduct and expects to defend vigorously.
• Segment Reporting Change: Effective Q1 2026, the company consolidated its reporting segments from four to two: "Cannabis" and "Storz & Bickel."

Investor Verification Checklist

• Going Concern Mitigation: Verify the sufficiency of the $126.2M cash balance and remaining ATM capacity against the upcoming US$50M debt prepayment obligations and recurring operating losses.
• Margin Sustainability: Assess whether the 25% gross margin is sustainable given the cited headwinds of freight costs and new product launch expenses.
• Canopy USA Valuation: Review the fair value adjustments on Canopy USA investments (Equity Method and Loan Receivable), which significantly impact the "Other income (expense)" line and net loss.
• Legal Exposure: Monitor the status of the SEC investigation into BioSteel and the class action lawsuits regarding the Claybourne product launch and gross margin disclosures.
• Debt Covenants: Confirm compliance with the amended Credit Facility covenants, particularly liquidity requirements, following the recent debt restructuring and prepayments.